Actym Therapeutics, Inc.
- Biotech or pharma, therapeutic R&D
Actym Therapeutics has engineered a new drug modality harnessing the power of a genetically modified bacterial vehicle to safely deliver therapeutic payloads to specific tissues. Our STACT™ (S. Typhimurium Anti-Cancer Therapy) platform is a precisely engineered bacterial delivery vehicle that is designed to be safely systemically administered and deliver multiple therapeutic payloads that are amplified and produced locally at the disease site, thereby avoiding therapeutic limiting systemic toxicity experienced when the payloads have been administered by other means. Our first asset, ACTM-838, is currently being evaluated in a phase 1a/1b clinical trial in patients with advanced solid tumors.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}